TD Cowen analyst Marc Frahm has maintained their bullish stance on RPTX stock, giving a Buy rating on March 7.
Marc Frahm has given his Buy rating due to a combination of factors including Repare Therapeutics’ strategic focus and financial positioning. The company has decided to concentrate its efforts on its promising Phase I clinical programs, RP-3467 and RP-1664, which are expected to yield topline data in the latter part of 2025. This strategic reprioritization is seen as a positive move, allowing the company to allocate resources more efficiently towards potentially high-impact therapies.
Additionally, despite reporting net losses, Repare maintains a solid cash position, which is projected to sustain operations into late 2027. This financial stability, coupled with the potential of their clinical programs, underpins the Buy rating. The company’s decision to discontinue less promising projects and focus on RP-3467 and RP-1664, which have shown promising preclinical results, further supports the positive outlook on Repare’s stock.
According to TipRanks, Frahm is a 4-star analyst with an average return of 4.7% and a 38.13% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Blueprint Medicines.
In another report released on March 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.